Thermodynamic basis for comparative photobiomodulation dosing with multiple wavelengths to direct odontoblast differentiation

Young, Nicholas; Maximiano, Vinícius; Arany, Praveen R.

doi:10.1002/jbio.202100398

Cited by 13 publications

(14 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ‘ one-size-fits-all ’ protocols or ‘ point-and-shoot ’ approach should no longer be acceptable for PBM treatments for its broad range of clinical applications. Rationalized dosimetry, including individual wavelength photon energy (photonic fluence), appropriate delivery technique, and clinical judgment of targeted biological responses are essential for optimal clinical therapeutic outcomes ( 62 , 63 ).…”

Section: Resultsmentioning

confidence: 99%

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

et al. 2022

View full text Add to dashboard Cite

DisclaimerThis article is based on recommendations from the 12th WALT Congress, Nice, October 3-6, 2018, and a follow-up review of the existing data and the clinical observations of an international multidisciplinary panel of clinicians and researchers with expertise in the area of supportive care in cancer and/or PBM clinical application and dosimetry. This article is informational in nature. As with all clinical materials, this paper should be used with a clear understanding that continued research and practice could result in new insights and recommendations. The review reflects the collective opinion and, as such, does not necessarily represent the opinion of any individual author. In no event shall the authors be liable for any decision made or action taken in reliance on the proposed protocols.ObjectiveThis position paper reviews the potential prophylactic and therapeutic effects of photobiomodulation (PBM) on side effects of cancer therapy, including chemotherapy (CT), radiation therapy (RT), and hematopoietic stem cell transplantation (HSCT).BackgroundThere is a considerable body of evidence supporting the efficacy of PBM for preventing oral mucositis (OM) in patients undergoing RT for head and neck cancer (HNC), CT, or HSCT. This could enhance patients’ quality of life, adherence to the prescribed cancer therapy, and treatment outcomes while reducing the cost of cancer care.MethodsA literature review on PBM effectiveness and dosimetry considerations for managing certain complications of cancer therapy were conducted. A systematic review was conducted when numerous randomized controlled trials were available. Results were presented and discussed at an international consensus meeting at the World Association of photobiomoduLation Therapy (WALT) meeting in 2018 that included world expert oncologists, radiation oncologists, oral oncologists, and oral medicine professionals, physicists, engineers, and oncology researchers. The potential mechanism of action of PBM and evidence of PBM efficacy through reported outcomes for individual indications were assessed.ResultsThere is a large body of evidence demonstrating the efficacy of PBM for preventing OM in certain cancer patient populations, as recently outlined by the Multinational Association for Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Building on these, the WALT group outlines evidence and prescribed PBM treatment parameters for prophylactic and therapeutic use in supportive care for radiodermatitis, dysphagia, xerostomia, dysgeusia, trismus, mucosal and bone necrosis, lymphedema, hand-foot syndrome, alopecia, oral and dermatologic chronic graft-versus-host disease, voice/speech alterations, peripheral neuropathy, and late fibrosis amongst cancer survivors.ConclusionsThere is robust evidence for using PBM to prevent and treat a broad range of complications in cancer care. Specific clinical practice guidelines or evidence-based expert consensus recommendations are provided. These recommendations are aimed at improving the clinical utilization of PBM therapy in supportive cancer care and promoting research in this field. It is anticipated these guidelines will be revised periodically.

show abstract

Section: Resultsmentioning

confidence: 99%

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Mice were randomly divided into four groups: (1) AC8 mice without any treatment/controls (AC group; n = 7); (2) AC8 mice treated with PBM (AC + T group; n = 8); (3) wild‐type mice without any treatment/controls (WT group; n = 9); and (4) wild‐type mice treated with PBM (WT + T group; n = 8). Mice in AC + T and WT + T groups received near‐infrared LED light exposure at 25 mW/cm 2 for 120 s at 850 nm for 1 Einstein (4.5 p.J/cm 2 photonic fluence or the conventional dose of 3 J/cm 2 ) for 5 days per week 23 . Mice were placed under a LED light source (Bio900, Platinum LED Inc) at a fixed distance in their original cages without cage covers, and light irradiance was calibrated using an optical power meter (ThorLabs Inc).…”

Section: Methodsmentioning

confidence: 99%

“…Mice in AC + T and WT + T groups received near-infrared LED light exposure at 25 mW/cm 2 for 120 s at 850 nm for 1 Einstein (4.5 p.J/cm 2 photonic fluence or the conventional dose of 3 J/cm 2 ) for 5 days per week. 23 Mice were placed under a LED light source (Bio900, Platinum LED Inc) at a fixed distance in their original cages without cage covers, and light irradiance was calibrated using an optical power meter (ThorLabs Inc). The mice were subjected to a whole-body treatment while they were awake and freely moving in their cage.…”

Section: Photobiomodulation Therapymentioning

confidence: 99%

Photobiomodulation therapy mitigates cardiovascular aging and improves survival

Syed¹,

Ahmet²,

Chakir³

et al. 2023

Lasers Surg Med

Self Cite

View full text Add to dashboard Cite

Background: Photobiomodulation (PBM) therapy, a form of low-dose light therapy, has been noted to be effective in several age-associated chronic diseases such as hypertension and atherosclerosis. Here, we examined the effects of PBM therapy on age-associated cardiovascular changes in a mouse model of accelerated cardiac aging. Methods: Fourteen months old Adenylyl cyclase type VIII (AC8) overexpressing transgenic mice (n = 8) and their wild-type (WT) littermates (n = 8) were treated with daily exposure to Near-Infrared Light (850 nm) at 25 mW/cm 2 for 2 min each weekday for a total dose of 1 Einstein (4.5 p.J/cm 2 or fluence 3 J/cm 2 ) and compared to untreated controls over an 8-month period. PBM therapy was administered for 3.5 months (Early Treatment period), paused, due to Covid-19 restrictions for the following 3 months, and restarted again for 1.5 months. Serial echocardiography and gait analyses were performed at monthly intervals, and serum TGF-β1 levels were assessed following sacrifice. Results: During the Early Treatment period PBM treatments: reduced the ageassociated increases in left ventricular (LV) mass in both genotypes (p = 0.0003), reduced the LV end-diastolic volume (EDV) in AC8 (p = 0.04); and reduced the left atrial dimension in both genotypes (p = 0.02). PBM treatments substantially increased the LV ejection fraction (p = 0.03), reduced the aortic wall stiffness (p = 0.001), and improved gait symmetry, an index of neuro-muscular coordination (p = 0.005). The effects of PBM treatments, measured following the pause, persisted. Total TGF-β1 levels were significantly increased in circulation (serum) in AC8 following PBM treatments (p = 0.01). We observed a striking increase in cumulative survival in PBM-treated AC8 mice (100%; p = 0.01) compared to untreated AC8 mice (43%). Conclusion: PBM treatment mitigated age-associated cardiovascular remodeling and reduced cardiac function, improved neuromuscular coordination, and increased longevity in an experimental animal model. These responses correlate with increased TGF-β1 in circulation. Future mechanistic and dose optimization studies are necessary to assess these anti-aging effects of PBM, and validation in future controlled human studies is required for effective clinical translation.

show abstract

“…PBM dosimetry has raised significant interest in recent years, primarily due to its efficacy in a broad range of clinical applications, regardless of the underlying pathology and varying protocols. But since Mester's first description of its benefits, PBM has been used rather empirically as a magic wand, without actual knowledge of photobiological, molecular, and intercellular mechanisms of laser-tissue interaction that cannot be ignored [51]. The absence of clear guides for standardizing protocols description and data presentation remains an issue that can limit comparison among studies and the creation of coherent clinical practice guidelines.…”

Section: Discussionmentioning

confidence: 99%

“…Recent papers emerged in the literature regarding the possibility of enabling comparisons between protocols, creating a system of "dosing consistency, " which is effective with multiple combined wavelengths. Young et al suggested using the terms photonic fluence (p.J/cm 2 ) and "Einstein" (photonic fluence at 810 nm as a reference wavelength) [51]. This enables easy, universal interoperability between dose recommendations with different wavelengths.…”

Section: Discussionmentioning

confidence: 99%

Quality assessment of PBM protocols for oral complications in head and neck cancer patients: part 2

Gobbo

Arany

Merigo

et al. 2023

Support Care Cancer

Self Cite

View full text Add to dashboard Cite

Background: Radiotherapy and chemotherapy are frequently employed in head and neck cancer (HNC) patients causing significant side effects that impair life quality and prognosis. Photobiomodulation (PBM) has become a growing approach to managing such oral complications. Despite its proven efficacy and absence of contraindications, there is still a lack of universally accepted disease-specific PBM protocols.Objective: A narrative review was conducted to identify the current proposals relating to the use of PBM to treat complications of oncological treatments in HNC patients.Methods: An electronic search in PubMed and Scopus databases was performed with the following keywords: ("photobiomodulation" OR "PBM" OR "laser therapy" OR "LLLT" OR "laser") AND ("head and neck cancer" OR "oral cancer") AND ("mucositis" OR "oral mucositis" OR "dysgeusia" OR "oedema" OR "xerostomia" OR "dermatitis" OR "trismus") until October 2021.Results: A total of 35 papers were included in the narrative review. Oral mucositis was the most studied complication, and advisable protocols are conceivable. Although there is a growing interest in PBM to manage of xerostomia, radiodermatitis, pain, and trismus, literature is still scarce to propose a universally feasible protocol.Conclusions: PBM therapy could significantly prevent or reduce the severity of many side effects related to cancer therapies. More research is needed to obtain recommendations over the preferable parameters.

show abstract

Thermodynamic basis for comparative photobiomodulation dosing with multiple wavelengths to direct odontoblast differentiation

Cited by 13 publications

References 58 publications

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022

Photobiomodulation therapy mitigates cardiovascular aging and improves survival

Quality assessment of PBM protocols for oral complications in head and neck cancer patients: part 2

Contact Info

Product

Resources

About